LiCALS is a multi-centre double-blind randomised parallel group controlled trial of the efficacy , safety , and tolerability of lithium carbonate ( LiCO3 ) at doses to achieve stable ` therapeutic ' plasma levels ( 0.4-0 .8 mmol/L ) , plus standard treatment , versus matched placebo plus standard treatment , in patients with amyotrophic lateral sclerosis .
